Joshua Hummel

This inventor holds 12 USPTO granted patents and 18 published patent applications and 1 EPO patent. Top assignee: Incyte Corporation. Active years: 2021-2026.

USPTO Granted Patents = 12 (Patent Applications = 18)

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 5.4

ph-index = 5

Forward Citations = 63(Granted Patents)

Company Filing History:

12 out of 686

Incyte Corporation

patents

Years Active: 2021-2026

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12692276 - Tricyclic triazolo compounds as DGK inhibitors (2026-07-28),

2. 12600723 - Tetracyclic compounds as DGK inhibitors (2026-04-14),

3. 12600722 - Tetracyclic compounds as DGK inhibitors (2026-04-14),

4. 12466828 - BICYCLIC AMINES AS CDK2 INHIBITORS (2025-11-11),

5. 11981671 - Bicyclic pyrazolyl amines as CDK2 inhibitors (2024-05-14),

6. 11976073 - Bicyclic amines as CDK2 inhibitors (2024-05-07),

7. 11866426 - Benzothiazole compounds and uses thereof (2024-01-09),

8. 11542265 - Pyrazolopyrimidine compounds and uses thereof (2023-01-03),

9. 11472791 - Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors (2022-10-18),

10. 11299473 - Benzimidazole and indole compounds and uses thereof (2022-04-12),

11. 11014929 - Pyrazolopyrimidine compounds and uses thereof (2021-05-25),

12. 10899755 - Benzothiazole compounds and uses thereof (2021-01-26),

Title: Innovations of Joshua Hummel

Introduction

Joshua Hummel is a notable inventor based in Hockessin, Delaware. He has made significant contributions to the field of pharmaceuticals, particularly in the development of cancer treatments. With a total of eight patents to his name, Hummel's work is recognized for its potential impact on medical science.

Latest Patents

Hummel's latest patents include innovative compounds that serve as inhibitors of cyclin-dependent kinase 2 (CDK2). One of his patents, titled "Bicyclic pyrazolyl amines as CDK2 inhibitors," presents bicyclic amines of a specific formula that are effective in treating cancer. Another patent, "Bicyclic amines as CDK2 inhibitors," also focuses on similar compounds and their pharmaceutical applications. These inventions highlight Hummel's commitment to advancing cancer therapies.

Career Highlights

Joshua Hummel is currently associated with Incyte Corporation, a leading biopharmaceutical company. His work at Incyte has allowed him to collaborate with other talented professionals in the field. Hummel's dedication to research and innovation has positioned him as a key figure in the development of new therapeutic strategies.

Collaborations

Some of Hummel's notable coworkers include Wenqing Yao and Alexander Sokolsky. Their collaborative efforts contribute to the advancement of research and the successful development of new pharmaceutical products.

Conclusion

Joshua Hummel's contributions to the field of pharmaceuticals, particularly in cancer treatment, are commendable. His innovative patents and collaborations reflect his dedication to improving medical outcomes. Hummel's work continues to inspire advancements in the industry.